



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

MICROMED CONSULTING GROUP ANNOUNCES STRATEGIC PARTNERSHIP WITH ROBERTS CONSULTING & ENGINEERING

PETALUMA, CA (September 18, 2003)— Oculus Innovative Sciences (www.oculusis.com), announced today that the company's wholly owned subsidiary, MicroMed Consulting and Laboratory Services (www.micromedlabs.com), has entered into a strategic partnership with Roberts Consulting & Engineering of Encinitas, California. The firm, founded by Mark A. Roberts, has implemented quality systems and provided ongoing technical support to a wide range of clients from Fortune 500 companies to venture capital start-ups, in both the medical device and in vitro diagnostic industries.

Roberts, prior to opening his own consulting firm in 1998, served as manager of the Western U.S. office for TUV Product Service. In this position he managed a staff of medical device auditors and product experts. He was authorized as a lead auditor and product expert. He has also held management positions in operations, quality assurance, sterility assurance and product development with Titan Scan Systems, Becton Dickinson and Baxter Healthcare.

The strategic partnership expands Roberts' operations, providing his clients with enhanced capabilities such as the contract laboratory testing and consulting services of MicroMed's experienced staff. At the same time, MicroMed will benefit from Robert's vast knowledge of the industry as well as his well-earned reputation for excellence in his profession.

"We are excited," said Hoji Alimi, president and founder of Oculus. "This is a great partnership between the two companies."

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative services and technologies that can improve patient health worldwide. The company has at its foundation wholly owned subsidiaries, AquaMed Technologies, Inc. and MicroMed Laboratories, Inc., a division of Oculus providing testing and consulting services to the biotech industries. Oculus has overseen the evolution of the Microcyn 60 disinfectant from technology to product as well as the develop-

ment of an anti-cancer drug (L3) that shows promise in the prevention of many aggressive cancers including cervical cancer and melanomas. This same L3 compound has great potential in other applications based on its cell growth inhibition characteristics such as the drug-eluting stent products reducing restenosis. For more information, please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.